ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2817

Expression Patterns of Interferon Induced Genes in Newborns Exposed to Ro/SSA Autoantibodies in Utero

Gudny Ella Thorlacius1, Malin Hedlund1, Margarita Ivanchenko1, Vijole Ottosson1, Amina Ossoinak1, Linda Lagnefeldt1, Lars Rönnblom2, Sven-Erik Sonesson3, Maija-Leena Eloranta4 and Marie Wahren-Herlenius1, 1Unit of Experimental Rheumatology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 2Department of Medical Sciences, Section of Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden, 3Pediatric Cardiology Unit, Department of Women´s and Children´s Health, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, Stockholm, Sweden, 4Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Sweden, Uppsala, Sweden

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: autoantibodies, heart block, Interferons and systemic lupus erythematosus (SLE), Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Systemic Lupus Erythematosus – Human Etiology and Pathogenesis I

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: Women with Sjögren’s syndrome and autoantibodies against Ro/SSA are at risk for pregnancy complications, including neonatal lupus erythematosus (NLE) and a congenital heart block in the baby. Ro/SSA autoantibodies are also associated with expression of interferon (IFN) regulated genes. Treatment with hydroxychloroquine (HCQ), which alters type 1 IFN activity, is thought to reduce the risk of NLE. The pattern and magnitude of IFN expression and responses in Ro/SSA autoantibody exposed newborns has not been investigated.

Methods: Thirteen Ro/SSA autoantibody positive mothers either receiving no medication (Ro/SSA+) or treated with HCQ and/or azathioprine (Ro/SSA+T), and their newborn babies were included in the study, together with 8 healthy mother-baby pairs (HC). Blood was drawn from the mother and baby (cord) at birth, with immediate separation into plasma and PBMC. mRNA expression levels were measured using microarrays and used for calculating IFN scores. Cell surface expression of molecules was investigated by flow cytometry, and IFN-α in plasma and supernatants was analyzed by immunoassay. The ability of PBMCs from newborns to produce IFN-α in response to autoantibody exposure was tested by stimulation with 10% plasma in cell culture for 24h.

Results: As expected, mRNA expression patterns in cells of SSA+ mothers showed enrichment of type I IFN pathways compared to HC mothers, and mothers from the Ro/SSA+ group had a higher IFN score and higher levels of IFN-α than HC mothers. Notably, also in newborns of Ro/SSA+ mothers, there was an enrichment of type I IFN pathways and high IFN score compared to newborns of HC mothers, and maternal and baby IFN scores had a significant, positive correlation (Pearson r=0.8128, p<0.0001). However, babies in the Ro/SSA+T group, whose mothers received immunomodulatory treatment, had an IFN score with values comparable to HC babies, while the maternal Ro/SSA+T IFN scores did not differ from those of non-treated mothers. Activation of CD14+ monocytes, in the form of increased MHC class II surface expression was observed in the Ro/SSA+ exposed newborns. PBMCs from both HC and Ro/SSA+ newborns cultured with Ro/SSA+ plasma produced IFN-α.

Conclusion: Babies exposed to Ro/SSA autoantibodies in utero have circulating IFN-α, an IFN-signature in their PBMCs and increased MHC class II expression on the cell surface of monocytes, which was partly reversed by maternal treatment with HCQ or other immunomodulatory drugs. PBMCs from babies are capable of producing IFN-α after exposure to Ro/SSA+ plasma. There is a measurable activation of the type I IFN system in Ro/SSA autoantibody exposed fetuses which may contribute to the risk of NLE.


Disclosure: G. E. Thorlacius, None; M. Hedlund, None; M. Ivanchenko, None; V. Ottosson, None; A. Ossoinak, None; L. Lagnefeldt, None; L. Rönnblom, None; S. E. Sonesson, None; M. L. Eloranta, None; M. Wahren-Herlenius, None.

To cite this abstract in AMA style:

Thorlacius GE, Hedlund M, Ivanchenko M, Ottosson V, Ossoinak A, Lagnefeldt L, Rönnblom L, Sonesson SE, Eloranta ML, Wahren-Herlenius M. Expression Patterns of Interferon Induced Genes in Newborns Exposed to Ro/SSA Autoantibodies in Utero [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/expression-patterns-of-interferon-induced-genes-in-newborns-exposed-to-rossa-autoantibodies-in-utero/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/expression-patterns-of-interferon-induced-genes-in-newborns-exposed-to-rossa-autoantibodies-in-utero/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology